Immune tolerance management company Cell Source Inc. (OTC: CLCS) could be on the radars of investors this morning. Yesterday the company hit the news wires after it provided a key update with regards to the presentation of preclinical data.
Significant Breakthrough
The company revealed yesterday that it had made a presentation of strong preclinical data at the 2024 American Society of Hematology (ASH) Annual Meeting. In the news release, Cell Source revealed that the research demonstrated that Veto Cell technology, its proprietary technology, was able to overcome a key barrier. The barrier in question was a particularly critical one in the allogeneic call therapy-natural killer cell-mediated rejection space. It was a significant new development for the company, and it would be interesting to see if it leads to any traction in its stock this morning or not.
Further Information
“Our results help to unravel the mechanism by which anti-viral CD8 central memory veto cells overcome NK-mediated rejection of mismatched hemopoietic transplants,” said study lead Dr. Yair Reisner, Professor of Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center. “These findings represent a significant step toward overcoming barriers in the development of off-the-shelf CAR T cell therapies, an important area of focus within the field of cancer immunotherapy.”
Quote from Dr. Yair Reisner:
The company stated that the study, titled “Overcoming NK Cell-Mediated Allograft Rejection by Anti-Third Party Central Memory Veto CD8 T Cells through Down-Regulation of the Activating Receptor DNAM-1 on Alloreactive NK Cells,” demonstrated the ability of the technology to suppress NK level activity. However, more importantly, the suppression was achieved without the proliferation of host T-cells or GvHD (graft versus host disease).
